New England Journal of Medicine· 2013Q1

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin, André Goy et al.

1,691citations
Q1SCImago
2013year

Short summary

Oral ibrutinib achieved a 68% overall response rate in 111 patients with relapsed or refractory mantle-cell lymphoma, with a median response duration of 17.5 months.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pathology and Forensic Medicine

Pathology and Forensic MedicineMedicine